Sign In
Buy TEM
$50.56
-1.76 (-3.36%)
At Close: Jun 16, 2026
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting
08:30am, Tuesday, 26'th May 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for present
Tempus AI: Taking Advantage Of Investor Myopia
09:43am, Friday, 22'nd May 2026
Tempus AI is a precision medicine leader leveraging AI and a unique data estate, with significant partnerships and a rapidly growing contract backlog exceeding $1 billion. TEM's recent share price dec
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and
4 Heavily Shorted AI Stocks to Watch Right Now
02:19pm, Wednesday, 20'th May 2026
BigBear.ai Holdings (BBAI), C3.ai (AI), SoundHound AI (SOUN), and Tempus AI (TEM) are all heavily shorted
7 Healthcare AI Stocks Under $50 With Huge Upside Potential
07:35am, Monday, 18'th May 2026
Healthcare AI stocks have been hammered in 2026, with several names down 30% to 65% year to date even as their underlying platforms keep maturing.
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE
Ambry Genetics' CARE Program® Wins 2026 MedTech Breakthrough Award for “Best Overall Health Informatics Solution”
06:00am, Monday, 11'th May 2026
ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), today announced that its CARE Program (Compr
Tempus AI: My Pick For An Oncoming Boom In Demand For Data-Driven Precision Medicine
01:25pm, Friday, 08'th May 2026
Tempus AI, Inc. is positioned as a data-driven precision medicine leader, leveraging AI and a vast multi-modal patient database to drive diagnostics and biopharma partnerships. TEM's dual business mod
3 Stocks Poised to Disrupt the Healthcare Market by 2030
07:30am, Friday, 08'th May 2026
The old healthcare model is breaking down.
Tempus Announces Pricing of Upsized Offering of $400.0 Million of Convertible Senior Notes
12:59am, Friday, 08'th May 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the pricing of $
Tempus AI, Inc. Announces Proposed Convertible Senior Notes Offering to Optimize Capital Structure and Reduce Interest Expense
07:11am, Thursday, 07'th May 2026
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (“Tempus”) (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced its intent to of
Tempus AI: Another Post-Earnings Dip Worth Buying
12:29am, Thursday, 07'th May 2026
Tempus AI presents a compelling long-term opportunity, with strong data adoption and an expanding addressable market beyond Oncology. Q1 showed mixed results: robust Oncology testing, Hereditary weakn
TEM Q1 Loss Narrower Than Expected, Revenues Beat, Stock Down
12:50pm, Wednesday, 06'th May 2026
Tempus AI posts narrower Q1 loss and strong 36% revenue growth, but shares slide after-market as operating loss and rising costs weigh on sentiment.
Lucent Diagnostics Announces Collaboration with Tempus to Integrate Blood-Based Alzheimer's Biomarker Testing into Clinical Workflows
08:00am, Wednesday, 06'th May 2026
BILLERICA, Mass.--(BUSINESS WIRE)--Lucent Diagnostics, a brand of Quanterix Corporation (NASDAQ: QTRX), today announced a collaboration with Tempus AI Inc. (NASDAQ: TEM), a technology company leading
Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript
11:11pm, Tuesday, 05'th May 2026
Tempus AI, Inc. (TEM) Q1 2026 Earnings Call Transcript
